TB-500
Availability Not yet prescribable · sold for research use only
What it is
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein that binds actin and takes part in cell migration and tissue repair. The fragment and the full protein are not the same molecule, which matters, because most of the science quoted in TB-500 marketing was done on the full protein.
Why people take it
It circulates as a repair peptide, reached for after soft-tissue injury, a nagging tendon, or a long rehab that has stalled. The appeal is a repair signal that works on connective tissue rather than muscle bulk.
How it's delivered
Some clinics advertise subcutaneous TB-500 injections alongside rehabilitation. No approved product exists. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound TB-500 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing TB-500; its Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records. Outside those conditions, sourcing, concentration, and sterility depend on the pharmacy or vendor rather than on a reviewed label.
Where the evidence stands
Full-length thymosin beta-4 reached real clinical trials as RGN-259, an eye drop, where a physician-sponsored phase 2 study reported improvement in signs and symptoms of severe dry eye. That is the strongest human data in the family, and it concerns an eye drop for a corneal condition, not an injection for a torn tendon. TB-500 itself has no completed human efficacy trial. Regulators are still deciding what to do with it: FDA removed its Category 2 entry following nomination withdrawal in April 2026, while retaining the published safety concerns. WADA prohibits thymosin beta-4 at all times.
Estimated cost
- No approved product and no verified reference price
- Not covered by insurance
Who offers it
We don't list providers for TB-500. There is no approved product, and we haven't verified any provider against the conditions of HHS's draft October 2026 interim compounding policy. Anything sold online as a research chemical is outside that policy.
Go deeper
The compound page, TB-500 in the Peptide Explorer, is the depth layer. The lane guide, Peptides for Muscle Repair and Injury Recovery, covers what separates a fragment from its parent protein and how to judge a repair claim.
Longevity.io is for educational purposes only and is not medical advice. Whether TB-500 belongs in a plan is a conversation for a clinician who knows the whole picture. Confirm eligibility, product source, and pricing directly with any provider.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
